Showing 2451-2460 of 4166 results for "".
- J&J Vision Introduces Artificial-Intelligence Powered Virtual Assistant for Contact Lenseshttps://modernod.com/news/jj-vision-introduces-artificial-intelligence-powered-virtual-assistant-for-contact-lenses/2480195/Johnson & Johnson Vision introduced Andy, a virtual assistant chatbot powered by artificial intelligence (AI). Andy is designed to help guide U.S. consumers throughout their Acuvue brand contact lens journey – from those considering contact lenses for the first time to long-term wearers. The
- CXL Ophthalmics Appoints Tiffany Haynes as Vice President of Clinical Operationshttps://modernod.com/news/cxl-ophthalmics-appoints-tiffany-haynes-as-vice-president-of-clinical-operations/2481468/CXL Ophthalmics announced that Tiffany Haynes has been appointed as Vice President of Clinical Operations. With more than 25 years of experience in ophthalmology, Ms. Haynes previously served as Global Director, Medical Affairs for Johnson & Johnson Vision. There, she was respo
- Opthea Presenting Clinical Data at ARVO 2022 Annual Meetinghttps://modernod.com/news/opthea-presenting-clinical-data-at-arvo-2022-annual-meeting/2480820/Opthea announced the presentation of novel clinical data at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2022 conference, taking place in Denver, Colorado from May 1-4, 2022 and virtually from May 11-12, 2022. Jason Slakter, MD, of
- Orasis Pharmaceuticals Concludes Phase 3 Clinical Trials for Presbyopia Candidatehttps://modernod.com/news/orasis-pharmaceuticals-concludes-phase-3-clinical-trials-for-presbyopia-candidate/2480699/Orasis Pharmaceuticals announced the completion of its NEAR-1 and NEAR-2 phase 3 clinical studies. “Orasis is committed to reshaping vision possibilities by developing a presbyopia eye drop with the patient in mind,” said Elad Kedar, Chief Executive Officer of Orasis. &ldquo
- Novaliq to Present Scientific and Clinical Research During the 2018 ARVO Meeting in Honoluluhttps://modernod.com/news/novaliq-to-present-scientific-and-clinical-research-during-the-2018-arvo-meeting-in-honolulu/2480208/Novaliq announced that four scientific posters will be presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) meeting in Honolulu, Hawaii (April 29-May 3). The variety of data to be presented reflects Novaliq’s dedication to science and clinical research. With th
- Notal Vision Announces Publication of First Pilot Study of Daily Self-Imaging With Patient-Operated Home OCT in Wet AMD Patientshttps://modernod.com/news/notal-vision-announces-publication-of-first-pilot-study-of-daily-self-imaging-with-patient-operated-home-oct-in-wet-amd-patients/2479356/Notal Vision announced that results from the first prospective longitudinal pilot study of daily, home-based self-imaging with their investigational, patient-operated home OCT for wet age-related macular degeneration
- Vision Innovation Partners Announces Suspension of Most Office Services, Warby Parker Informs Customers of Store Closures for Two Weeks Due to Coronavirushttps://modernod.com/news/vision-innovation-partners-announces-suspension-of-most-office-services-warby-parker-informs-customers-of-store-closures-for-two-weeks-due-to-coronavirus/2477399/Two vision care businesses are among the first groups in the U.S. to announce that they will be instituting closures of their offices and store networks to prevent the spread of the coronavirus (COVID-19), according to a VisionMonday
- Ocuphire Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol Eye Drops for Night Vision Disturbanceshttps://modernod.com/news/ocuphire-announces-positive-topline-results-from-lynx-1-phase-3-trial-evaluating-nyxol-eye-drops-for-night-vision-disturbances/2480873/Ocuphire Pharma announced positive topline results from the LYNX-1 phase 3 pivotal clinical trial investigating its product candidate Nyxol for night (or dim light) vision disturbances (NVD). More than 650 subjects have now been exposed to Nyxol. NVD is a condition i
- Participants of Experimental CRISPR Gene Editing Trial See Vision Improvehttps://modernod.com/news/participants-of-experimental-crispr-gene-editing-trial-see-vision-improve/2482277/About 79% of clinical trial participants experienced measurable improvement after receiving experimental, CRISPR-based gene editing that is designed to fix a rare form of blindness, according to a paper published in the New England Journal of Medicine, the National Eye Institut
- More Adults with Vision Loss Seeking Help Staying Connected During Pandemichttps://modernod.com/news/more-adults-with-vision-loss-seeking-help-staying-connected-during-pandemic/2478772/Since the onset of COVID-19 those with visual impairments have faced disproportionate vulnerabilities from living in extended isolation. Newly released data has shown that clinical depression within the visually impaired community is being reported at nearly three times the level than the general